

The Initial Journey of Patients with Metastatic Pancreatic Cancer (PaCTO Project): A Nationwide Survey among Portuguese Specialist Physicians

Anabela G. Barros^a Hélder Mansinho^b Nuno Couto^c Manuel R. Teixeira^{d,e}
Fernanda S. Tonin^{f,g} Rudolfo Francisco^h Filipa Duarte-Ramos^{i,j,k}

^aDepartment of Medical Oncology, University Hospital of Coimbra, Coimbra, Portugal; ^bHemato Oncology Department, Garcia de Orta Hospital, Almada, Portugal; ^cDigestive Unit, Champalimaud Clinical Centre, Champalimaud Research Centre, Lisbon, Portugal; ^dDepartment of Laboratory Genetics, Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center, Porto, Portugal; ^eCancer Genetics Group, IPO Porto Research Center (CI-IPOP)/RISE@CI-IPOP (Health Research Network), School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal; ^fPharmaceutical Sciences Postgraduate Program, Federal University of Parana, Curitiba, Brazil; ^gH&TRC–Health & Technology Research Center, ESTeSL– Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon, Portugal; ^hOncology-Medical Department, AstraZeneca, Barcarena, Portugal; ⁱDepartment of Pharmacy, Pharmacology and Health Technologies, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal; ^jResearch Institute for Medicine (iMed.Ulisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal; ^kEPIUnit, Instituto de Saúde Pública da Universidade do Porto (ISPUP), Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Porto, Portugal

Keywords

Pancreatic neoplasms · Immunotherapy ·
Cross-sectional studies · Surveys and Questionnaires

Abstract

Introduction: We aimed to characterize the initial healthcare journey of metastatic pancreatic ductal adenocarcinoma (mPDAC) patients in Portugal, including healthcare provision and factors affecting therapeutic decisions, namely BRCA mutations testing. **Methods:** This is a descriptive cross-sectional, web-based survey using a convenience sampling approach. Portuguese oncologists and pathologists that routinely work with mPDAC patients from the different geographical regions and settings were invited to participate in the study via email (December 2020). Descriptive

statistical analyses were performed, with categorical variables reported as absolute and relative frequencies, and continuous variables with non-normal distribution as median and interquartile range (IQR) (Stata v.15.0). **Results:** Seventy physicians participated in the study (43 oncologists, 27 pathologists). According to the responses, a median of 28 patients per center (IQR 12–70) was diagnosed with PDAC in the previous year; 22 of them referring (IQR 8–70) to mPDAC. The pointed median time from patients' first hospital admission until disease diagnosis/staging is between 2 and 4 weeks. Endoscopic ultrasound with fine-needle biopsy is available in most hospitals (86%). Around 50% of physicians request BRCA testing; the assessment of additional biomarkers besides BRCA is requested by 40% of professionals. Half of them stated that BRCA testing should be requested earlier–upon histological diagnosis, especially because the

median time for results is of 4.0 weeks (IQR 4–8). PARP inhibitors such as olaparib, when available, would be the therapy of choice for most oncologists (71%) if no disease progression occurs after 4 months. Treatments' selection is usually grounded on clinical criteria (e.g., performance status, liver function). Around 45% of patients use FOLFIRINOX/mFOLFIRINOX as the first-line therapy. Gemcitabine + nab-paclitaxel is used by 35% of patients as the second-line therapy. **Conclusions:** Physicians in Portugal support the increasing role of patient-tailored treatments in mPDAC, whose selection should be grounded on tumoral subtyping and molecular profiling. Further efforts to develop multidisciplinary teams, standardized clinical practice, and optimize the implementation of new target therapies are needed.

© 2023 The Author(s).
Published by S. Karger AG, Basel

A jornada inicial dos doentes com cancro de pâncreas metastático (projeto PaCTO): um inquérito nacional a médicos especialistas portugueses

Palavras Chave

Cancro pancreático · Imunoterapia · Estudo transversal · Questionários

Resumo

Introdução: Este estudo teve como objetivo caracterizar o percurso inicial dos doentes com adenocarcinoma ductal pancreático metastático (ACDPm) em Portugal, incluindo a prestação de cuidados de saúde e determinação de fatores que afetam as decisões terapêuticas, nomeadamente o teste de mutações BRCA. **Métodos:** Trata-se de um estudo descritivo transversal (web-based) usando uma abordagem de amostragem por conveniência. Médicos oncologistas e anatomopatologistas portugueses dedicados ao ACDPm e de diferentes regiões geográficas e instituições foram convidados a participar do estudo por email (Dez-2020). Foram realizadas análises estatísticas descritivas, com variáveis categóricas relatadas como frequências absolutas e relativas, e variáveis contínuas com distribuição não-normal como mediana e intervalo interquartil (IIQ) (Stata v.15.0). **Resultados:** Setenta médicos participaram do estudo (43 oncologistas, 27 patologistas). De acordo com as respostas, uma mediana de 28 doentes por centro (IIQ 12–70) foi diagnosticada com ACDP no ano anterior; 22 deles (IIQ 8–70) referentes a ACDPm. O tempo médio desde a primeira admissão hospitalar dos doentes até o

diagnóstico/estadiamento da doença foi entre 2–4 semanas. A ultrassonografia endoscópica com biópsia por agulha fina é realizada pela maioria dos hospitais (86%). Aproximadamente 50% dos médicos referem solicitar o teste BRCA; a avaliação de biomarcadores adicionais além do BRCA é solicitada por 40% dos profissionais. Metade dos médicos assume que o teste BRCA deveria ser solicitado mais precocemente – durante o diagnóstico histológico, principalmente porque o tempo médio para obtenção do resultado é de 4,0 semanas (IIQ 4–8). Os inibidores PARP, como o olaparibe, quando disponíveis, seriam a terapia de escolha para a maioria dos oncologistas (71%) caso não haja progressão da doença após quatro meses. A seleção dos tratamentos é usualmente baseada em critérios clínicos (por exemplo, *performance status*, função hepática). Em cerca de 45% dos doentes é utilizado FOLFIRINOX/mFOLFIRINOX como terapia de primeira linha. Um esquema com Gemcitabina + nab-paclitaxel é usado em 35% dos doentes como terapia de segunda linha. **Conclusões:** Os médicos em Portugal apoiam o papel crescente do tratamento individualizado no ACDPm, cuja seleção deve ser baseada na subtipagem tumoral e no perfil molecular. São necessários mais esforços para capacitar as equipas multidisciplinares, desenvolver práticas clínicas padronizadas e otimizar a implementação de novas terapias-alvo.

© 2023 The Author(s).
Published by S. Karger AG, Basel

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is currently the seventh leading cause of cancer death worldwide with 495,773 new cases and 466,003 deaths reported in 2020 [1]. In the next few years, PDAC is estimated to become the second cause of cancer mortality in developed countries – including in Portugal where annual deaths should surpass 2,000 ($n = 2,137$; 95% CI, 1,862–2,413) by 2035 reflecting an increase of 51% [2–4]. Without treatment, median survival of metastatic PDAC (mPDAC) lies between 3 and 6 months. Although few patients (15–20%) are amenable to surgery combined with adjuvant chemotherapy, overall survival is of 11–25 months [5, 6].

The mainstay of current therapeutic approach for mPDAC is the combination of cytotoxic drugs such as FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin), gemcitabine with nab-paclitaxel, and gemcitabine

plus capecitabine [7–10]. Additional attempts to further improve survival include modifying the sequence of combination regimens, adding other cytotoxic agents, or performing maintenance strategies [11–13].

The recent implementation of target therapies was especially important for the management of pancreatic tumors, given that an unstable genotype with numerous structural variations (e.g., BRCA1, BRCA2, or PALB2 genes or mutational signatures of DNA-damage repair deficiency) is present in about 10–15% of patients. Germline mutations in BRCA genes are identifiable in around 4–7% of patients with mPDAC [14–16]. As these cells with a deficient DNA repair are usually sensitive to adenosine diphosphate-ribose polymerase (PARP) inhibition [17, 18], there is growing role for PARP inhibitors as potential therapies [19–21]. The efficacy of the PARP inhibitor olaparib as a single agent in germline BRCA mutation and PDAC was initially suggested in a phase II trial that demonstrated median progression-free survival and overall survival rates of 4.6 and 9.8 months, respectively [19]. The effect of olaparib as a maintenance therapy in patients who had a germline BRCA1 or BRCA2 mutation with mPDAC not progressing during the first-line platinum-based chemotherapy was assessed in the phase III POLO trial [22] showing progression-free survivals of 7.4 months versus 3.8 months in placebo ($p = 0.004$) [23]. Based on these findings, olaparib was approved by the US Food and Drug Administration (FDA) on December 2019 and by the European Medicines Agency (EMA) in July 2020 and is currently recommended by the ASCO guidelines (2020) for the maintenance treatment of adult patients with germline BRCA mutations mPDAC whose disease has not progressed during at least 16 weeks of the first-line platinum-based chemotherapy [24]. Other drugs that are being currently tested in this scenario include nimotuzumab (anti-EGFR), durvalumab (anti-PDL-1), nivolumab (anti-PD-1) [13].

Nonetheless, the late integration of target therapies in clinical practice accentuates the need for multidisciplinary and consensual decision-making processes, which arouses new challenges, as well as changes in work routines, that are daily faced by pancreatic cancer specialists. Several questions regarding patients' journey still need to be clarified, including the use of new techniques for disease early diagnosis and staging (e.g., endoscopic ultrasound-guided fine-needle biopsy – EUS-FNB), identification of biomarkers and criteria that influence therapies' selection [25–28]. Thus, the aim of this study was to characterize the initial healthcare journey of

mPDAC patients in Portugal (after reaching a referral center), including healthcare provision, and major factors currently affecting therapeutic decisions, namely BRCA mutations testing.

Materials and Methods

Study Design and Variables

A descriptive cross-sectional web-based survey (Google form) using a convenience sampling approach was performed. Portuguese oncologists and pathologists that routinely work with mPDAC patients from the different geographical regions and settings (public, private hospitals) were invited to participate in the study via email (December 2020) (the list of potentially eligible physicians with clinical practice experience in this field was provided by the Grupo de Estudos em Cancro Digestivo–GECD – Portugal). Physicians were fully informed regarding the nature of the study, the procedures for data recording, and the voluntary nature of their participation. Responders provided their informed consent before survey's completion, and anonymity was guaranteed. Participants' withdrawal was allowed at any time. This study was waived of bioethical approval (National Legislation-Law 21/2014) because it does not contain any intervention on human subjects nor individual health data collection.

The questionnaire was divided into two sections that aim to assess physicians' perception on mPDAC patients journey in Portugal in the previous year, 2019 (i.e., to avoid bias from COVID-19 potential disruptions in health services). The first section (18-items) was answered by both oncologists and pathologists and included information on: sociodemographic data (e.g., medical specialty, working place), current histopathological diagnosis, disease staging procedures, and biomarkers evaluation. The second part of the questionnaire (12-items) was intended only for oncologists and covered topics on therapeutic approaches and complementary procedures for mPDAC management.

The questionnaire was specifically developed for this study by the Coordinator Committee (Anabela G. Barros [oncologist], Hélder Mansinho [oncologist], Nuno Couto [oncologist], Manuel R. Teixeira [pathologist], Filipa Duarte-Ramos [pharmacist, epidemiologist]). Responders took an average time of 10 min to complete the survey. Standards for scientific research were performed according to the Declaration of Helsinki. The complete questionnaire (original language, Portuguese) is available in online supplementary Appendix (for all online suppl. material, see <https://doi.org/10.1159/000533178>).

Data Analysis

The normality of the variables was assessed using Kolmogorov-Smirnov and Shapiro-Wilk tests with additional visual inspection of Q-Q plots. Descriptive statistics were used to summarize the data, with absolute and relative frequencies to describe categorical variables and median and interquartile range (IQR) for continuous non-normal variables. The association between categorical variables was assessed through Pearson's χ^2 test (alternatively, when few observations, e.g., less than 5, exist, the Fisher's exact test was

Table 1. Physicians' perception on mPDAC characterization

Variables (categories)	Oncologists (n = 43), n (%)	Pathologists (n = 27), n (%)	p value ¹
Working institution			
Public	33 (76.7)	16 (59.3)	0.031*
Private	5 (11.6)	1 (3.7)	
Both	5 (11.6)	10 (37.0)	
Geographical region (Portugal)			
Center	5 (11.6)	4 (14.8)	0.844
Lisbon region	19 (44.2)	10 (37.0)	
North	16 (37.2)	12 (44.4)	
Others (Algarve, Azores, Madeira)	3 (7.0)	1 (3.7)	
Request molecular profiling for pancreatic adenocarcinoma ^a			
No	5 (21.7)	6 (37.5)	0.298
Only for BRCA mutation	10 (43.5)	3 (18.8)	
BRCA and other biomarkers	8 (34.8)	7 (43.8)	
When is BCRA mutation profiling done ^b			
During histological diagnosis	3 (14.3)	4 (57.1)	0.050
During metastatic disease diagnosis	4 (19.1)	0 (0.0)	0.545
During multidisciplinary consultation	0 (0.0)	1 (14.3)	0.250
During the oncologic consultation	13 (61.9)	2 (28.6)	0.198
When lacking therapeutic alternatives	1 (4.8)	0 (0.0)	1.000
When should BCRA mutation profiling be done ^c			
During histological diagnosis	7 (58.3)	7 (53.8)	1.000
During metastatic disease diagnosis	6 (50.0)	0 (0.0)	0.005
During multidisciplinary consultation	3 (25.0)	0 (0.0)	0.095
During the oncologic consultation	1 (8.3)	1 (7.7)	1.000
When lacking therapeutic alternatives	0 (0.0)	0 (0.0)	–
If germline mutation profiling is not requested, when should BRCA be done ^d			
During histological diagnosis	5 (26.3)	10 (58.8)	0.089
During metastatic disease diagnosis	8 (42.1)	2 (11.8)	0.065
During multidisciplinary consultation	1 (5.3)	4 (23.5)	0.167
During the oncologic consultation	2 (10.5)	1 (5.9)	1.000
When lacking therapeutic alternatives	3 (15.8)	0 (0.0)	0.230
Cases of BRCA1 and BRCA2 profiling request ^e			
According to family history	3 (25.0)	2 (15.4)	0.299
According to patients' age at diagnosis	2 (16.7)	0 (0.0)	
All cases	7 (58.3)	11 (84.6)	
Samples of BRCA1 and BRCA2 profiling ^e			
Only in peripheral blood (germline mutations)	14 (73.7)	4 (50.0)	0.310
Only in the tumor (somatic or germline mutations)	1 (5.3)	1 (12.5)	
On the tumor and peripheral blood	4 (21.1)	3 (37.5)	
Mutation's profiling request ^e			
Only BRCA1 and BRCA2	10 (52.6)	4 (50.0)	1.000
Genetic panel	9 (47.4)	4 (50.0)	
Median time for obtaining BRCA results ^f			
<6 weeks	9 (47.4)	7 (100.0)	0.023
≥6 weeks	10 (52.6)	0 (0.0)	

Given the small sample size and few observations for some variables, no test was performed aiming at avoiding misleading interpretation (i.e., only percentages are presented). *Adjusted post hoc analysis for the pairs (Fisher's exact test): public × private ($p = 0.654$), public × both ($p = 0.101$), private × both ($p = 0.127$). ^aTotal sample $n = 39$ (23 + 16); ^bTotal sample $n = 28$ (21 + 7); ^cTotal sample $n = 25$ (12 + 13); ^dTotal sample $n = 36$ (19 + 17); ^eTotal sample $n = 27$ (19 + 8); ^fTotal sample $n = 26$ (19 + 7). ¹Pearson χ^2 test or Fisher's exact test.

used). Analyses were conducted in Stata Statistical Software version 15.0 SE (College Station, TX: StataCorp LL, USA) and *p* values below 0.05 were considered statistically significant.

Results

Diagnosis of mPDAC: Oncologists and Pathologists' Overview

Overall, 70 physicians (from *n* = 34 invited Centers in Portugal) participated in the study, of which 43 were oncologists and 27 were pathologists, mostly from Lisbon and Vale do Tejo (41.4%) and North (40.0%) regions. Table 1 shows the sociodemographic characteristics of the participants and their perception on the initial journey of patients with mPDAC in Portugal. Most physicians (*n* = 49; 70.0%) work only in public health institutions. Although oncologists may have a greater representation in this setting (76.8% vs. 59.3% of pathologists), pathologists also labor in both public and private centers (37.0% vs. 11.6% of oncologists).

The most frequent types of pancreatic cancer diagnosed in the physicians' institutions are adenocarcinoma—found in 90% of patients, followed by undifferentiated tumors (5%). Adenosquamous carcinoma and cystadenocarcinoma are poorly reported (around 2% of cases). According to the clinicians, in the past year (12 months – perception over the period from Jan to Dec 2019), a median of 28 patients (IQR 12–70) was diagnosed with PDAC in their center; 22 (IQR 8–70) of them referred to mPDAC. Endoscopic procedures, like ERCP (endoscopic retrograde cholangiopancreatography) or endoscopic ultrasound, complemented with cytology or forceps biopsy sampling, are performed in a median of 50% of admitted patients (IQR 30–70) as part of the histological diagnosis. Metastasis biopsy (percutaneous) is performed in around 50% of cases (IQR 30–70). Almost half of the oncologists (43.5%) request only BRCA mutation as molecular/genetic profiling for mPDAC, while pathologists (43.8%) additionally request the assessment of other biomarkers (e.g., PALB2, ATM, MLH1, MSH2, MSH6 e CDKN2A). Yet around one-third of pathologists stated they do never request this procedure (37.5%) (see Table 1). According to most physicians (*n* = 18/27; 66.7%), BRCA1 and BRCA2 profiling are done in all cases regardless of patient's age or family history, using only peripheral blood samples for germline mutations.

According to most oncologists (61.9%), BRCA mutation profiling request is usually performed during the oncologic consultation in their centers, which is slightly different from the perceived clinical routine reported by the pathologists (see Table 1). Most phy-

sicians (*n* = 14 out of 25 responding to this question; 56.0%) recommended BRCA testing to be requested earlier – upon histological diagnosis, especially because the overall median time for results is of 4.0 weeks (IQR 4–8). Yet half of the oncologists (52.6%) believe that this median time is usually over 6 weeks, while for all the responding pathologists this procedure is significantly faster, occurring within 6 weeks (*p* = 0.023). It was estimated that around 5% of all patients diagnosed in the physicians' centers present germline mutations. Most pathologists agree that BRCA test should be done during histological diagnosis (58.8%) or requested upon multidisciplinary consultation (23.5%) if germline mutation profiling is not requested at that time; conversely, around 40% of oncologists believe this procedure should be performed at diagnosis of metastatic disease (see Table 1).

Management of mPDAC: Oncologists' Perception

Oncologists (*n* = 43) additionally described the current practices for mPDAC management in Portugal, which are depicted in Tables 2, 3. Most physicians state that Oncology (53.5%), Imagiology (51.2%), Gastroenterology (46.5%), and Hepato bilio pancreatic surgery (46.5%) are part of multidisciplinary teams, being other specialties less frequently reported.

Over 65% of oncologists are satisfied or very satisfied with the support provided by different hospital services for the management of the oncologic patients, especially with nursing staff and pain units. Yet around one-third of experts believe that there is room for improvement in the nutrition and palliative care units (see Fig. 1).

EUS-FNB is available in most institutions/hospitals (according to 86.4% of clinicians) as primary diagnosis approach, being the results generally released in less than 2 weeks—even if performed outside the physicians' hospital (Table 2). Yet, this procedure (EUS-FNB) for primitive tumor and others such as PET-CT and CT pancreas protocol are often required as complementary exams (according to around 40–50% of physicians) for disease diagnosis and staging. ERCP was also frequently mentioned by the physicians as a complementary procedure, although this is not mandatory for pancreatic cancer. Conversely, abdominal MR and CA 19.9 are rarely performed as complementary procedures (see Fig. 2).

According to the experts, median time from first hospital admission until mPDAC diagnosis and staging is usually between 2 and 4 weeks. PARP inhibitors, when approved, would be the therapy of choice for most oncologists (71.4%) for patients with BRCA mutations

Table 2. Oncologists' perception on mPDAC patients' journey

Variables (categories)	Oncologists (n = 43), n (%)
Clinical specialties in the multidisciplinary consultation*	
Oncology	23 (53.5)
General surgery	14 (32.6)
Hepato bilio pancreatic surgery	20 (46.5)
Pathological anatomy/genetics	16 (32.2)
Gastroenterology	20 (46.5)
Imaging	22 (51.2)
Radiotherapy	17 (39.5)
Does your hospital perform endoscopic ultrasound with fine-needle biopsy exam? ^a	
Yes	19 (86.4)
No	3 (13.6)
Median time from first hospital admission to mPDAC diagnosis and staging ^b	
<2 weeks	2 (8.7)
Between 2 and 4 weeks	13 (56.5)
>4 weeks	8 (34.8)
Treatment of choice in case of no progression after 4 months of platinum-based therapy ^c	
Maintain therapy as long as there is clinical response and tolerance	4 (19.0)
Therapy discontinuation and patient monitoring	1 (4.8)
Maintain therapy + PARP inhibitor	1 (4.8)
PARP inhibitor	15 (71.4)
Criteria that influence 1st line therapy decision-making*	
Performance status	22 (51.3)
Symptoms	6 (13.9)
Liver function	14 (32.6)
Age	7 (16.3)
Comorbidities	14 (32.6)
Patients' preferences	3 (6.9)
Criteria that influence 2nd line therapy decision-making*	
1st line protocol	21 (48.8)
Performance status	22 (51.2)
Symptoms	2 (4.7)
Liver function	6 (13.9)
Age	1 (2.3)
Comorbidities	9 (20.9)
Patients' preferences	6 (13.9)

*Physicians could select more than one answer (sum of variables' category may be over 100%). ^aSample n = 22; ^bSample n = 23; ^cSample n = 21.

without progression after 4 months of chemotherapy treatment. The first-line treatments are usually selected after an oncology evaluation, grounded mostly on clinical criteria (e.g., performance status, liver function) and patients' comorbidities. The second-line therapy selection usually considers the previous first-line protocols and patients' performance status. During these therapeutic decisions, less than 15% of physicians consider patients preferences (see Table 2). According to the oncologists, FOLFIRINOX/mFOLFIRINOX is used as the first-line therapy in 45.0% of patients [IQR 30–50], followed by gemcitabine plus nab-paclitaxel (32.5% [IQR 20–40]). This last regimen is also com-

monly used as the second-line therapy (35.0% [IQR 10–50]) followed by gemcitabine alone (25.0% [IQR 10–40]) (Table 3).

Discussion

This study was triggered by the ongoing debate on the need for improving pancreatic cancer diagnosis and reducing the burden of this disease caused by the high rates of morbidity and mortality in Portugal. Through a nationwide survey with physicians that routinely manage mPDAC patients (i.e., pathologists and oncologists) from

Table 3. Patients in use of the first and second-line therapies according to oncologists' practice

Therapies	Percentage of patients, median [interquartile range]
1st line therapies	
FOLFIRINOX/ mFOLFIRINOX	45.0 [IQR 30–50]
Gemcitabine + nab- paclitaxel	32.5 [IQR 20–40]
Gemcitabine	10.0 [IQR 10–25]
FOLFOX/CAPOX	5.0 [IQR 0–10]
5-FU/LV/Capecitabine	2.0 [IQR 0–5]
2nd line therapies	
FOLFIRINOX/ mFOLFIRINOX	5.0 [IQR 0–10]
Gemcitabine + nab- paclitaxel	35.0 [IQR 10–50]
Gemcitabine	25.0 [IQR 10–40]
FOLFOX/OFF	15.0 [IQR 5–30]
5-FU/LV/Capecitabine	5.0 [IQR 5–20]
Irinotecan	0.0 [IQR 0–10]

all Portuguese regions, we were able to identify their perception on some barriers for rapid diagnosis and beginning of treatment – including heterogeneous practices related to criteria for requesting molecular tests and delays for obtaining BRCA results that may impact on clinical and economic outcomes.

According to the Global Cancer Observatory, in 2020 the estimated crude incidence and prevalence (5-years) rates for PDAC in Portugal were of 17.6 and 11.7 per 100,000 habitants, respectively, with a mortality rate (2020) of 5.9 per 100,000 habitants [1]. In our study, we found pancreatic adenocarcinoma as the most reported type of tumor among patients, with around 30 cases per institution per year in Portugal, of which around 75% diagnosed in a metastatic stage or in progression, with a large dispersion (varying from 8 to 70 patients/institution/year). According to the Portuguese National Health System (SNS), the country currently has around 55,000 registered physicians, of which 30,000 work on public health institutions, especially in Lisbon and North regions that concentrate approximately 60% of all healthcare professionals [29]. These figures highlight some geographical asymmetries that are also reflected in our study.

The goal of rapid investigation and treatment of cancer is to maximize cure rate for patients with early-stage disease, to increase the number of patients with resectable disease, and to avoid tumor growth and upstaging [24]. We found that physicians perform upper

endoscopic ultrasound with cytology, biopsy procedures, and metastasis investigation in around half of patients admitted in their institution as part of the histological diagnosis. Complementary procedures such as PET-CT and CA 19.9 are fairly used. Although ERCP is not mandatory for pancreatic cancer (i.e., therapeutic procedure indicated in case of obstructive jaundice), it was frequently mentioned by the physicians as a complementary requested procedure for diagnosis. These differences may occur due to the limited access to these techniques or availability of resources in each center, together with the current local protocols for clinical practice. Nonetheless, precise staging of PDAC, including TNM staging and determination of tumor resectability is highly recommended by international guidelines and should be always performed [24, 30]. In the last few decades, the importance of EUS-FNB significantly increased worldwide, as it represents a step forward to a more accurate diagnosis and, consequently, to a more frequent use of neoadjuvant chemotherapy and personalized medicine. This approach has surpassed percutaneous sampling techniques, as it provides tissue core biopsies, allowing histological assessment. New generation FNB needles demonstrated a diagnostic accuracy of over 95% for solid pancreatic lesions and provide samples appropriate for ancillary testing, such as immunohistochemistry and tumor molecular profiling [25, 31].

We also verify the need to enlarge molecular characterization in patients with mPDAC, as only around 40% of physicians request the assessment of additional biomarkers besides BRCA1 and BRCA2. These data are in consonance with previous literature stating that although clinically relevant subtypes of mPDAC exist, molecular profiling is not yet standard in clinical care. Nonetheless, several groups and international cancer networks now advocate for universal multigene germline testing for all patients, irrespective of family history or age at diagnosis [24, 30]. The current challenges for expanding molecular analyses and precision medicine for mPDAC include, among others, the heterogeneous cellular composition of biopsy specimens, the low neoplastic cellularity of tumors and rapid progression of the disease and decisions related to clinical practice and available resources (e.g., human and technical resources, access to drug therapies toward different mutations' treatment) [32, 33]. Interestingly, a study implementing a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA sequencing for mPDAC showed that therapeutically relevant genomic alterations were identified in 48% of patients and pathogenic/likely pathogenic germline alterations in 18%.

Fig. 1. Oncologists' perception on the support provided by the different services on mPDAC patients' management.





Fig. 2. Oncologists' perception on the use of complementary procedures for the diagnosis of mPDAC.



This results, promoted in around one-third of patients a change in clinical management as a result of genomic data. The most important alterations found were germline or somatic alterations on DNA-damage repair genes (in 40%) and almost 3% had oncogenic in-frame BRAF deletions, which could confer sensitivity to MAPK pathway inhibition. Besides, the aforementioned technical issues, the clinical application of a molecular profiling in mPDAC patients should also consider the difficulty to propose non-approved drugs in this setting, especially considering the high costs and the doubts in response associated with those drugs. These results additionally highlight the difficulties in implementing these protocols in real-world settings [34].

Another dilemma in mPDAC management in Portugal refers to the discrepancies between pathologists and oncologists perceived clinical routines, especially

regarding time to mutations' profiling requests and results. This may occur as most pathologists usually require BRCA mutation characterization earlier—during the histological diagnosis, and receive the results within 6 weeks. On the other hand, most oncologists refer to this procedure only during the oncologic consultation in their centers, with half of them obtaining the results after 6 weeks. In this scenario, the pointed median time from patients' admission until mPDAC diagnosis may be longer than 2 months. Comparatively, in England, the median time from patients' first presentation to the healthcare system to diagnosis is of 76 days (IQR 28–161) for metastatic pancreatic cancer, which represents around 2–3 months [35]. In Italy, the overall median diagnostic delay for PDAC is of 2 months, varying from 1 to 5 months [36]. Regarding only the mutation profiling process for advanced cancers, in the USA, the median

time to transmission of results to patients after testing is of around 1 month, but with a very large dispersion (ranging from 0 to 16 months) [37].

These findings highlight the need to standardize and accelerate disease diagnosis and staging aiming at reducing the times for decision-making regarding patients' treatment. In an international level, both germline and tumor BRCA mutational analyses are being increasingly used for selecting patients who could benefit from PARP inhibitors. These tests should be requested during the initial diagnosis of the patient, thus providing appropriate information on all aspects associated with the disease and allowing prompt actions for managing mPDAC [38].

One approach to enhance clinical practice homogeneity and reduce time for cancer diagnosis and treatment is by implementing functional multidisciplinary (MDT) teams' meetings and referral centers [39]. However, several factors influencing presentation of all pancreatic cancer patients to MDT meetings still exist. We found that clinical specialties such as general surgery, pathology, gastroenterology, and radiotherapy – that are paramount for PDAC management, participate in only around one-third of the so-called MDT consultations. The rationale for MDT is to be multidimensional, aiming at ensuring that complex patients receive all care services, including timely diagnosis and treatment, to meet their individual needs. These teams should bring together the expertise and skills of different professionals to assess, plan, and manage care jointly [40]. A recent study performed in Australia showed that barriers influencing MDT practices include: absence of palliative care representation, the number of MDT meetings, the cumulative cost of staff time, the lack of capacity to discuss all patients within the allotted time and reduced confidence to participate in discussions [41]. These factors can lead to a reduced quality of care management and failure to reach decisions in around 27–52% of cases [42]. Additionally, a systematic review showed that MDT decisions frequently lack on considering nursing personnel opinions and patients preferences [42]. In our study, although most oncologists feel satisfied with the support provided by different hospital services, including nursing staff and pain units, there is room for improvement in coordination with the nutrition and palliative care units. This is important as a study recently demonstrated that around 93% of patients with PDAC need palliative care referral, 45% receive palliative chemotherapy and around 80% have a dietitian referral [43]. In this scenario, key enablers influencing MDT practices include a strong organi-

zational focus (e.g., leadership, training) that should be strengthened with the development of agreed evidence-based protocols and referral pathways, use of technology (e.g., videoconferences), resource allocation and capabilities, and a culture that fosters widespread collaboration for all stages of PDAC (e.g., motivation to provide good quality care) [41, 42].

According to surveyed oncologists, the first-line treatments for mPDAC in Portugal are currently selected grounded on clinical criteria (e.g., performance status, liver function) and patients' comorbidities, being chemotherapy combinations such as FOLFIRINOX or mFOLFIRINOX or gemcitabine plus nab-paclitaxel the most prescribed. Selection of the second-line therapies follows similar patterns, being grounded on the use of previous chemotherapy protocols and patients' performance status. Factors such as the access to therapies (e.g., regulatory issues, costs, reimbursement criteria) and real-world practices in the country (e.g., delayed or lack of molecular profiling, inflexible treatment protocols, physicians' preferences) can be associated with this heterogenous scenario. This also highlights the difficulties for approving and implementing new target drugs, such as olaparib, into daily practice, which could support answering the needs of both patients and healthcare professionals in the country. Yet, around 70% of oncologists in our study stated that PARP inhibitors, when approved, would be the therapeutic choice for patients with BRCA mutations without progression after 4 months of chemotherapy treatment.

Our study has some limitations. Non-probabilistic convenience sampling in cross-sectional studies may carry out a bias in data collection and due to underrepresentation of subgroups considering that more committed responders usually get involved in mPDAC care. However, our inferences were grounded on the results obtained with this sample, without further extrapolation. We also acknowledged the relatively small sample size with limited number of participants reported by physicians from some regions of the country. Yet, this geographical asymmetry is similar to that observed in the country in previous studies [2]. We were able to portray the perception of both pathologists and oncologists that routinely manage mPDAC patients in Portugal. Although the questionnaire was applied in the end of 2020, which could raise concerns about the impact of the COVID-19 on the clinical activities evaluated in this study, all questions were retrospective regarding the routinely scenario previous to the pandemic.

Portuguese physicians support the increasing role of target therapies and patient-tailored treatments for mPDAC, whose selection should be grounded on tumoral subtyping and molecular profiling by means of accurate diagnostic and staging techniques. However, further efforts from both healthcare institutions and the health system to develop functional multidisciplinary teams and provide technical and qualified human resources are required. This may reduce the time between patients' diagnosis and beginning of treatment and standardize daily clinical practice in the country. Additionally, there is a need to optimize the approval and implementation process of new target therapies for conditions such as mPDAC that would benefit from the availability of further therapeutic strategies.

Acknowledgments

The authors would like to acknowledge Dr. Filipa Duarte-Ramos (FDR LDA Company, Portugal) for medical writing support that was funded by AstraZeneca in accordance with Good Publications Practice (GPP3) guidelines (<http://www.ismpp.org/gpp3>). We also acknowledge every physician participating in the survey.

Statement of Ethics

This study was waived of bioethical approval (National Legislation-Law 21/2014) because it does not contain any intervention on human subjects nor individual health data collection.

References

- 1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209–49.
- 2 Marques da Costa P, Tato Marinho R, Cortez-Pinto H, Costa L, Velosa J. Twenty-five years of increasing mortality from pancreatic cancer in Portugal. *Pancreas.* 2020;49(1):e2–3.
- 3 Are C, Chowdhury S, Ahmad H, Ravipati A, Song T, Shrikandhe S, et al. Predictive global trends in the incidence and mortality of pancreatic cancer based on geographic location, socio-economic status, and demographic shift. *J Surg Oncol.* 2016;114(6):736–42.
- 4 Wong MCS, Jiang JY, Liang M, Fang Y, Yeung MS, Sung JY. Global temporal patterns of pancreatic cancer and association with socio-economic development. *Sci Rep.* 2017;7(1):3165.
- 5 Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res.* 2014;74(11):2913–21.
- 6 Carrato A, Falcone A, Ducreux M, Valle JW, Parnaby A, Djazouli K, et al. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs. *J Gastrointest Cancer.* 2015; 46(3):201–11.
- 7 Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med.* 2011; 364(19):1817–25.
- 8 Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med.* 2013;369(18):1691–703.
- 9 Rapposelli IG, Casadei-Gardini A, Vivaldi C, Bartolini G, Bernardini L, Passardi A, et al. Equivalent efficacy but different safety profiles of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer. *Biomolecules.* 2021;11(6):780.
- 10 Giommoni E, Maiello E, Vaccaro V, Rondini E, Vivaldi C, Tortora G, et al. Activity and safety of NAB-FOLFIRI and NAB-FOLFOX as first-line treatment for metastatic pancreatic cancer (NabucCO study). *Curr Oncol.* 2021;28(3):1761–72.
- 11 Christenson ES, Jaffee E, Azad NS. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. *Lancet Oncol.* 2020;21(3):e135–45.
- 12 Hue JJ, Bingmer K, Sugumar K, Markt SC, Rothermel LD, Hardacre JM, et al. Immunotherapy is associated with a survival benefit in patients receiving chemotherapy for metastatic pancreatic cancer. *J Pancreat Cancer.* 2021;7(1):31–8.
- 13 Hammel P, Vitellius C, Boisteau E, Wisniewski M, Colle E, Hilmi M, et al. Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors. *Ther Adv Med Oncol.* 2020; 12:1758835920937949.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Funding Sources

This work was supported by AstraZeneca. The funders had no role in study design, data collection, and analysis nor in the preparation of the manuscript.

Author Contributions

Anabela G. Barros, Rudolfo Francisco, and Filipa Duarte-Ramos designed the study and wrote the protocol with contributions from Hélder Mansinho, Nuno Couto, Manuel R. Teixeira, and Fernanda S. Tonin. Data acquisition was performed by Anabela G. Barros, Hélder Mansinho, Nuno Couto, and Manuel R. Teixeira. Filipa Duarte-Ramos and Fernanda S. Tonin wrote the draft of the manuscript with contributions from Anabela G. Barros, Hélder Mansinho, Nuno Couto, Manuel R. Teixeira, and Rudolfo Francisco and analyzed the data, which was interpreted by all authors; the final version of the manuscript was approved by all authors.

Data Availability Statement

All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

- 14 Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. *J Clin Oncol*. 2015;33(28):3124–9.
- 15 Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. *Nature*. 2015;518(7540):495–501.
- 16 Heeke AL, Pishvaian MJ, Lynce F, Xiu J, Brody JR, Chen WJ, et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. *JCO Precis Oncol*. 2018;2018(2):1–13.
- 17 O'Connor MJ. Targeting the DNA damage response in cancer. *Mol Cell*. 2015;60(4):547–60.
- 18 Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. *Cancer Res*. 2012;72(21):5588–99.
- 19 Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. *J Clin Oncol*. 2015;33(3):244–50.
- 20 Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. *Br J Cancer*. 2014;111(6):1132–8.
- 21 Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. *N Engl J Med*. 2017;377(6):523–33.
- 22 Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. *N Engl J Med*. 2019;381(4):317–27.
- 23 Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. *Ann Oncol*. 2019;30(12):1959–68.
- 24 Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, et al. Metastatic pancreatic cancer: ASCO guideline update. *J Clin Oncol*. 2020;38(27):3217–30.
- 25 Marques S, Bispo M, Rio-Tinto R, Fidalgo P, Deviere J. The impact of recent advances in endoscopic ultrasound-guided tissue acquisition on the management of pancreatic cancer. *GE Port J Gastroenterol*. 2021;28(3):185–92.
- 26 Sivapalan L, Kocher HM, Ross-Adams H, Chelala C. Molecular profiling of ctDNA in pancreatic cancer: opportunities and challenges for clinical application. *Pancreatology*. 2021;21(2):363–78.
- 27 Arias-Pinilla GA, Modjtahedi H. Therapeutic application of monoclonal antibodies in pancreatic cancer: advances, challenges and future opportunities. *Cancers*. 2021;13(8):1781.
- 28 Diab M, Azmi A, Mohammad R, Philip PA. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. *Expert Opin Pharmacother*. 2019;20(5):535–46.
- 29 Sistema Nacional de Saúde (SNS). *Trabalhadores por grupo profissional*; 2021. Available from: <https://www.sns.gov.pt/transparencia/>.
- 30 National Comprehensive Cancer Network (NCCN). *Pancreatic Cancer Guidelines*; 2021. Available from: <https://www.nccn.org/patients/guidelines/content/PDF/pancreatic-patient.pdf>.
- 31 Bispo M, Marques S, Rio-Tinto R, Fidalgo P, Deviere J. The role of endoscopic ultrasound in pancreatic cancer staging in the era of neoadjuvant therapy and personalised medicine. *GE Port J Gastroenterol*. 2021;28(2):111–20.
- 32 Yurgelun MB. Germline testing for individuals with pancreatic cancer: the benefits and challenges to casting a wider net. *J Clin Oncol*. 2017;35(30):3375–7.
- 33 Aung KL, Fischer SE, Denroche RE, Jang GH, Dodd A, Creighton S, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. *Clin Cancer Res*. 2018;24(6):1344–54.
- 34 Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. *Cancer Discov*. 2018;8(9):1096–111.
- 35 Walter FM, Mills K, Mendonca SC, Abel GA, Basu B, Carroll N, et al. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study. *Lancet Gastroenterol Hepatol*. 2016;1(4):298–306.
- 36 Stornello C, Archibugi L, Stigliano S, Vanella G, Graglia B, Capalbo C, et al. Diagnostic delay does not influence survival of pancreatic cancer patients. *United Eur Gastroenterol J*. 2020;8(1):81–90.
- 37 Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. *JAMA*. 2017;318(9):825–35.
- 38 Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. *Eur J Cancer*. 2021;146:30–47.
- 39 Kirkegard J, Aahlin EK, Al-Saiddi M, Bratlie SO, Coolsen M, de Haas RJ, et al. Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. *Br J Surg*. 2019;106(6):756–64.
- 40 Patkar V, Acosta D, Davidson T, Jones A, Fox J, Keshtgar M. Cancer multidisciplinary team meetings: evidence, challenges, and the role of clinical decision support technology. *Int J Breast Cancer*. 2011;2011:831605.
- 41 Maharaj AD, Evans SM, Zalberg JR, Ioannou LJ, Graco M, Croagh D, et al. Barriers and enablers to the implementation of multidisciplinary team meetings: a qualitative study using the theoretical domains framework. *BMJ Qual Saf*. 2021;30(10):792–803.
- 42 Lamb BW, Brown KF, Nagpal K, Vincent C, Green JS, Sevdalis N. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. *Ann Surg Oncol*. 2011;18(8):2116–25.
- 43 Choi CC, Choi J, Houli N, Smith M, Usatoff V, Lipton L, et al. Evaluation of palliative treatments in unresectable pancreatic cancer. *ANZ J Surg*. 2021;91(5):915–20.